Fourier Intelligence wraps up ACRM trip, looks to unlock greater growth potential
The domestic leader in rehabilitation robotics is keen to inject new momentum into cooperation with partners like Barrow Neurological Institute, Arizona State University and Shirley Ryan AbilityLab.
Shanghai, November 13 – Fourier Intelligence, a leading maker of rehabilitation robots, is poised to step up cooperation with established US rehabilitation centres following its participation in the recent 96th American Congress of Rehabilitation Medicine (ACRM) annual conference in Chicago.
This has been the third consecutive time for the Shanghai-based startup to attend the world's largest interdisciplinary rehabilitation research event (November 3-8), this year as an institutional members bronze sponsor.
Fourier Intelligence exhibited its flagship products, ArmMotus M2 robot, aimed at upper extremity rehabilitation, and ExoMotus X2, designed to help patients with movement impairment in their lower limbs.
According to Tai Zhi Kang, business development manager of Fourier Intelligence who was at the ACRM conference, the two robotic devices on display drew a large crowd to the company's booth. Visitors also expressed admiration for inventions such as the EXOPS (Exoskeleton & Robotics Open Platform System), which Fourier Intelligence debuted early this year in Shanghai.
EXOPS allows for research and development activities based on existing hardware and algorithms developed by others, thereby freeing developers from the process of starting from scratch to design their own exoskeletons.
EXOPS has been the foundation for a series of tie-ups between Fourier Intelligence and world-class rehabilitation hospitals and clinics, such as the Chicago-based Shirley Ryan AbilityLab (formally known as Rehabilitation Institute Chicago). The two sides signed a memorandum (MoU) of understanding in June to apply cutting-edge robotics technology in the therapy of patients suffering mobility handicaps or neurological disorders.
"After the ACRM is over, the two devices will be transferred to our partners," said Tai. "ArmMotus M2 will go to Barrow Neurological Institute, while ExoMotus X2 will be shipped to Shirley Ryan AbilityLab as part of an in-kind contribution to the Leg + Walking Lab under the stewardship of Dr. Jose Pons."
He added Fourier Intelligence's participation in ACRM has provided the firm an opportunity to advance collaboration with existing MoU partners like Barrow Neurological Institute and Arizona State University. Barrow topped a ranking by the US News and World Report as America’s best neurology and neurosurgery hospital in 2019, while Arizona State University has been rated as the country’s No.1 university in terms of innovation for four years in a row.
"Our collaboration with Barrow Neurological Institute will be mainly focused on the clinical trial of Fourier Intelligence's device whereas partnership with Arizona State University would be on further research and development," said Tai.
Fourier Intelligence expects to broaden its influence across the US medtech landscape by leveraging these organizations’ good reputation. What's more, promotion of new practices in patient care, including "intelligent rehabilitation hub" and "robotic group therapy," will be central to the firm's strategy to make inroads in the US market.
In addition, Fourier Intelligence is looking to expand its ties with Shirley Ryan AbilityLab into wider areas that could involve more units under the No.1 rehabilitation institution in America. Work is already underway on collaboration with its Think + Speaking Lab, Arm + Hands Lab and Endurance Lab, Tai claimed.
About Fourier Intelligence
Fourier Intelligence is a technology-driven company, infusing creativity into the development of exoskeleton and rehabilitation robotics since 2015. Together with researchers, therapists and patients, we aim to excel in developing and redefining rehabilitation robotics solutions with interconnectable intelligent robotics technology by elevating user experience with an intuitive, easy-to-use system to enhance the lives of the both patients and therapists.
For investor and media inquiries, please contact:Mr Zen Koh (Deputy CEO / Chief Strategy Officer)